NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease - Wikidata - awgldk - TriplyDB

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

http://www.wikidata.org/entity/Q36089698

about

Nanotechnology: toxicologic pathology The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice.Optimizing NTS-polyplex as a tool for gene transfer to cultured dopamine neurons.Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra Activation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease.Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases.Focusing brain therapeutic interventions in space and time for Parkinson's disease.Antioxidant gene therapy against neuronal cell death.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Targeted delivery of nano-therapeutics for major disorders of the central nervous system.From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF)Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery.Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.Neurturin overexpression in dopaminergic neurons induces presynaptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion.Development of a Parenteral Formulation of NTS-Polyplex Nanoparticles for Clinical Purpose.Gene Therapy for Parkinson's Disease, An Update.

P2860

Q23909945-D3890787-01FF-4D0D-B6E7-7A0507C87B02 Q27316252-C2390957-CE2F-4B91-B001-5594F7D2C4AE Q33604560-8CAC96EB-7109-48EF-A9BF-870B125FD58B Q34540115-18D4F633-2EEF-466A-B332-A165241D82E0 Q34768987-B9A1A5F2-6BB2-4B37-88B1-83639E761B58 Q34936413-01A0742A-3F5C-4317-B59B-BF5D24AD6B5A Q35878528-8D233746-A725-49BE-8F8E-416AE79D601A Q36081720-7CBA05FD-4DEC-4E9D-980A-2772E1A83E49 Q36745293-4D948BC5-7188-4D81-840F-BDACE847FE2B Q37647941-F810EF93-B2F8-401B-AB4E-141D443287B9 Q38112216-2BA8E59A-529A-4FFC-A136-A26079A8B9E1 Q38116765-E3FE57E3-C93C-4E44-90B6-38C58CEB117B Q38168376-E463B50B-94F4-4222-9138-96B2C979EED2 Q38573732-EEA88C64-C1B1-4E90-8D2D-83D648578BAA Q38587566-BA1BEBA1-2651-4F17-97DB-5E335F919242 Q47162932-396F3112-000B-4EF0-8585-C531E81214C3 Q48308187-3EE435B0-1AE1-433C-A5B7-B029539CFE7D Q55418920-7C3C4A7B-9EF6-4218-B3A4-70C5CBCBEF4F

P2860

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

http://www.wikidata.org/entity/Q36089698

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

@ast

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

@en

type

label

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

@ast

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

@en

prefLabel

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

@ast

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

@en

P1433

Q36089698-1EB95C88-9483-4785-9494-97316A1B8540

P1476

Q36089698-E848B1B3-F9D8-43E8-896E-85E022D1F885

P2093

Q36089698-0BE73FE4-AB3F-41BF-92F0-C5CE278EC1AE

Q36089698-2CE61D9A-891A-47B3-B90D-6587138C70E5

Q36089698-391D1595-29AD-40D1-A595-8F6A16D02C4F

Q36089698-55A32169-DAB6-4BC8-A629-43BC2569D776

Q36089698-5A8843F8-6008-486F-BE12-196642F6B56B

Q36089698-805C00A3-128E-4672-95B0-6F15B6D11966

Q36089698-97C3BEC7-2872-426B-A01D-1AA0431E4EBE

Q36089698-CE42D9B5-DDC8-40E2-ABA4-9A1C373E11BA

P2860

Q36089698-0069589B-7ADC-402F-98AF-8439C186581B

Q36089698-00BD7D4B-879F-4A0F-BB24-C05AFD99E819

Q36089698-0243EEA2-7EC2-44B6-89C0-70C1968B3D2D

Q36089698-02A05EF3-DC36-40E7-8C14-15B0DA01FFF5

Q36089698-05195D99-0D28-4639-9165-FFEF1DC729A8

Q36089698-05BA0E4E-B2F8-4D7C-B332-B307FA0368FC

Q36089698-0825E85E-1803-434A-8AEE-F3E198F690A9

Q36089698-0935E327-098E-4893-AB9C-E4206EB1F18B

Q36089698-0B5D4B3B-08EF-4108-BEC9-D9462F548E6F

Q36089698-0B7F24A2-76BA-40E0-8CD9-6D6373E2C201

P304

Q36089698-335B6166-19C1-48CC-87C7-FB1A4CC35691

P31

Q36089698-A0C91361-FDC9-4F54-BCCC-FBDAD47E28A4

P356

Q36089698-F84EA1B2-AA42-4887-B270-A13056235DAC

P433

Q36089698-B1F4549C-DDC8-43E6-902C-18D5B0077570

P478

Q36089698-E518F318-49DC-4205-B02C-A43C6001F1E7

P50

Q36089698-5E3BE1FF-2CEB-479C-A8ED-A35184C8CEA1

P577

Q36089698-8F0956C6-36B1-4CA0-A0F1-C286609F3F4F

P5875

Q36089698-075B4423-D07D-4A1D-B9DD-38BA56F2A9EC

P698

Q36089698-82209DB2-8871-416A-A815-B22C597848B6

P921

Q36089698-EA578263-301F-4663-857E-4DDC80F9E4D5

Q36089698-FCEF1459-3108-4784-9D43-F14157189DAD

P932

Q36089698-F404530E-8BCC-47D2-A771-7DB4A409CC5B

P356

J.NANO.2012.02.009

P1433

Nanomedicine: Nanotechnology, Biology and Medicine

P1476

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

@en

P2093

Daniel Martinez-Fong

http://www.w3.org/2001/XMLSchema#string

David Reyes-Corona

http://www.w3.org/2001/XMLSchema#string

Ivan Navarro-Quiroga

http://www.w3.org/2001/XMLSchema#string

Juan A Gonzalez-Barrios

http://www.w3.org/2001/XMLSchema#string

Juan Armendáriz-Borunda

http://www.w3.org/2001/XMLSchema#string

Martha L Arango-Rodriguez

http://www.w3.org/2001/XMLSchema#string

Michael J Bannon

http://www.w3.org/2001/XMLSchema#string

Nancy G Hernandez-Chan

http://www.w3.org/2001/XMLSchema#string

P2860

The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor

Correlative ultrastructural distribution of neurotensin receptor proteins and binding sites in the rat substantia nigra

Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase

Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor

Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain

Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus

Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor

Polymer-based non-viral gene delivery as a concept for the treatment of cancer.

Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line

The GDNF family: signalling, biological functions and therapeutic value

P304

1052-1069

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NANO.2012.02.009

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Louis-Eric Trudeau

P577

2012-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221692200

http://www.w3.org/2001/XMLSchema#string

P698

22406187

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3394898

http://www.w3.org/2001/XMLSchema#string